Results 31 to 40 of about 75,891 (267)

Saphenous vein graft disease, pathophysiology, prevention, and treatment. A review of the literature

open access: yesJournal of cardiac surgery, 2020
The saphenous vein remains the most frequently used conduit for coronary artery bypass grafting, despite reported unsatisfactory long‐term patency rates.
G. Guida   +6 more
semanticscholar   +1 more source

Comparison between the STENTYS self-apposing bare metal and paclitaxel-eluting coronary stents for the treatment of saphenous vein grafts (ADEPT trial) [PDF]

open access: yes, 2018
Aims To describe the safety and performance of STENTYS self-expandable bare metal stents (BMS) versus paclitaxel-eluting stents (PES) in saphenous vein grafts (SVGs).
Amoroso, G. (Giovanni)   +6 more
core   +8 more sources

Aortocoronary saphenous vein graft aneurysm misdiagnosed as aortic arch aneurysm

open access: yesAnnals of Cardiac Anaesthesia, 2021
Coronary artery bypass grafting is the mainstay of revascularization worldwide. However, the most widely used saphenous vein grafts are related to a number of late sequelae.
Nikolaos A Papakonstantinou   +3 more
doaj   +1 more source

Managing coronary artery vein bypass graft stump pseudoaneurysm: a novel approach

open access: yesJournal of the Belgian Society of Radiology, 2012
We present a case of a pseudoaneurysm of the saphenous vein graft stump, which was managed with percutaneous thrombin injection. Aneurysms of a saphenous vein coronary bypass graft are rare and aneurysms of a bypass graft stump are even rarer.
V Rachapalli, R Evans, D Roberts
doaj   +1 more source

Long-term outcomes of omniflow II biosynthetic vascular graft in lower extremity arterial revascularization [PDF]

open access: yes, 2018
Background: This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.
Göncü, M.T.   +4 more
core   +1 more source

Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. [PDF]

open access: yes, 2006
Objective: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs). Design: Prospective multicentre study. Comparison with a control group.
Blindt, Ruediger   +5 more
core   +2 more sources

Gene Therapy for Cardiovascular Disease [PDF]

open access: yes, 2003
The last decade has seen substantial advances in the development of gene therapy strategies and vector technology for the treatment of a diverse number of diseases, with a view to translating the successes observed in animal models into the clinic ...
Baker, Andrew H.   +3 more
core   +4 more sources

Upregulation of miR-126-3p promotes human saphenous vein endothelial cell proliferation in vitro and prevents vein graft neointimal formation ex vivo and in vivo

open access: yesOncoTarget, 2017
Poor long-term patency of vein grafts remains an obstacle in coronary artery bypass grafting (CABG) surgery using an autologous saphenous vein graft. Recent studies have revealed that miR-126-3p promotes vascular integrity and angiogenesis.
Qingxi Qu   +8 more
semanticscholar   +1 more source

“Water running in my chest”: Delayed spontaneous rupture of an aortocoronary saphenous vein graft aneurysm

open access: yesClinical Case Reports, 2021
Saphenous vein graft aneurysm is an uncommon condition and knowledge about its natural history, and a multi‐specialty heart team approach is of utmost importance for better clinical outcomes.
Eric Gnall   +5 more
doaj   +1 more source

Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile [PDF]

open access: yes, 2013
<p>Background: Cardiovascular disorders, including coronary artery bypass graft failure and in-stent restenosis remain significant opportunities for the advancement of novel therapeutics that target neointimal hyperplasia, a characteristic of both ...
AA Soyombo   +47 more
core   +2 more sources

Home - About - Disclaimer - Privacy